EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement

Wen Zhou, Xiaojia Guo, Yang Liu, Zhengdong Hao, Songlin Chu, Liansheng Zhang, Lijuan Li

Case Reports in Oncology · 08.01.2025 · 18 (1) · 190-197

DOI: 10.1159/000542692 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 08.01.2025. Verfasst von Wen Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The PCM1-JAK2 rearrangement is generated through the t(8; 9)(p22; p24) translocation event. The myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) with PCM1-JAK2 rearrangement is the common types of MLN-eo with tyrosine kinase fusion genes (MLN-Eo-tk). MLN-Eo with PCM1-JAK2 rearrangement is a rare disease with a poor prognosis and no unified treatment guidelines. The response of disease to ruxolitinib may be transient and it may only serve as a temporary treatment prior to transplantation. Case Presentation: We report 1 patient diagnosed with MLN-Eo with PCM1-JAK2 rearrangement who exhibited resistance to ruxolitinib, subsequently received pegylated interferon (Peg-IFN) and lenalidomide. The Peg-IFN was discontinued due to adverse effects; the patient has been receiving lenalidomide monotherapy for a duration exceeding 2 years, achieving complete hematologic remission and molecular response, significant amelioration of symptoms, as well as regression of hepatosplenomegaly.

Conclusion

A case of MLN-Eo with PCM1-JAK2 rearrangement underwent continuous oral lenalidomide monotherapy for over 2 years. The patient achieved complete hematologic remission and molecular response during the long-term follow-up; however, a complete molecular remission was not attained. The underlying mechanism of lenalidomide in these diseases necessitates further comprehensive investigation through fundamental research and clinical trials.

Schlagwörter

Stichwörter der Autor:innen

LenalidomideMyeloproliferative neoplasmPCM1-JAK2Pegylated interferonRuxolitinib

Autor:innen und Institutionen

  • Department of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.

Zitieren

APA

Zhou, W., Guo, X., Liu, Y., Hao, Z., Chu, S., Zhang, L., & Li, L. (2025). A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement. Case Reports in Oncology, 18(1), 190-197. https://doi.org/10.1159/000542692

Vancouver

Zhou W, Guo X, Liu Y, Hao Z, Chu S, Zhang L, et al. A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement. Case Reports in Oncology. 2025;18(1):190-197. doi:10.1159/000542692

BibTeX
@article{Zhou2025,
  author = {Zhou, Wen and Guo, Xiaojia and Liu, Yang and Hao, Zhengdong and Chu, Songlin and Zhang, Liansheng and Li, Lijuan},
  title = {A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement},
  journal = {Case Reports in Oncology},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {190--197},
  doi = {10.1159/000542692}
}
Kostenlos starten →